ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈
生物活性靶点体外研究体内研究 用途与合成方法 MSDS ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈价格(试剂级) 上下游产品信息
| 中文名称 | ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 |
|---|---|
| 中文同义词 | ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈;RGS抑制剂(CCG-63802);化合物 T14897;化合物CCG-63802;CCG-63802,G蛋白信号传导4(RGS4)蛋白调节剂的抑制剂 |
| 英文名称 | alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile |
| 英文同义词 | α-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile;(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)a;(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)acry;alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile;CCG-63802;CCG 63802; CCG63802;(2E)-2-(1,3-Benzothiazol-2-yl)-3-[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]acrylonitrile;2-Benzothiazoleacetonitrile, α-[[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]- |
| CAS号 | 620112-78-9 |
| 分子式 | C26H18N4O2S |
| 分子量 | 450.51 |
| EINECS号 | |
| 相关类别 | G蛋白偶联受体&G蛋白;细胞生物学试剂 |
| Mol文件 | 620112-78-9.mol |
| 结构式 | ![ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 结构式](CAS2/GIF/620112-78-9.gif) |
ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 性质
| 沸点 | 547.9±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.31 |
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | 溶解度有限，溶于DMSO |
| 形态 | 固体 |
| 酸度系数(pKa) | -0.42±0.70(Predicted) |
| 颜色 | 粘黄色 |
CCG-63802 是一种选择性，可逆变构的 G 蛋白信号调节子 RGS4 抑制剂。CCG-63802 与 RGS4 特异性结合并阻断 RGS4-Gαo 相互作用，IC50 值为 1.9 μM。
|
RGS4 1.9 μM (IC 50 ) |
CCG-63802 (5 μM) inhibits regulators of G-protein signaling (RGS) proteins in the presence of BK (bradykinin) and 8-Br-cGMP (membrane-permeable analogue of cGMP), HEK-293 cells start to depolarize again.
CCG-63802 (0.05 mg/kg; intratracheal administration; once per week; 90 days) reduces RGS4 protein expression, leading to partially abrogate the attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling.
| Animal Model: | Forty female BALB/c mice aged 6-8 week old |
| Dosage: | 0.05 mg/kg |
| Administration: | Intratracheal administration; once per week; 90 days |
| Result: | CCG 63802 treatment in OVA +PGZ + CCG group significantly reduced RGS4 protein expression compared to OVA + PGZ group (P < 0.05) |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-70074 | ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 CCG-63802 | 620112-78-9 | 5mg | 660元 |
| 2024/04/30 | HY-70074 | ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 CCG-63802 | 620112-78-9 | 10mg | 1100元 |